The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line

Cancer Letters

Volumn 313, Issue 1, 2011, Pages 84-90

  Tsaur, Igor ^a   Makarević, Jasmina ^a   Hudak, Lukasz ^a   Juengel, Eva ^a   Kurosch, Martin ^a   Wiesner, Christoph ^a   Bartsch, Georg ^a   Harder, Sebastian ^a   Haferkamp, Axel ^a   Blaheta, Roman A ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Cdk1; Cyclin B; Everolimus resistance; Prostate cancer; Tumor growth

Indexed keywords

CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; EVEROLIMUS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL STRAIN PC3; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION;

BLOTTING, WESTERN; CDC2 PROTEIN KINASE; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN B; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; G2 PHASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INHIBITORY CONCENTRATION 50; MALE; MULTIPROTEIN COMPLEXES; PROSTATIC NEOPLASMS; RNA INTERFERENCE; SIROLIMUS;

EID: 80054123642     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.026     Document Type: Article

References (38)

1. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Théodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A. TAX 327 investigators, docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl. J. Med. 2004, 351:1502-1512.
2. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 2008, 26:242-245.
3. Don A.S., Zheng X.F. Recent clinical trials of mTOR-targeted cancer therapies. Rev. Recent Clin. Trials 2011, 6:24-35.
4. Pal S.K., Figlin R.A. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Target Oncol. 2011, 6:5-16.
5. Antonarakis E.S., Carducci M.A., Eisenberger M.A. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett. 2010, 291:1-13.
6. Basu B., Eisen T. Perspectives in drug development for metastatic renal cell cancer. Target Oncol. 2010, 5:139-156.
7. Sosman J.A., Puzanov I., Atkins M.B. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin. Cancer Res. 2007, 13:764s-769s.
8. Rini B.I., Atkins M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009, 10:992-1000.
9. Houk B.E., Bello C.L., Kang D., Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res. 2009, 15:2497-2506.
10. Escudier B., Szczylik C., Hutson T.E., Demkow T., Staehler M., Rolland F., Negrier S., Laferriere N., Scheuring U.J., Cella D., Shah S., Bukowski R.M. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009, 27:1280-1289.
11. Makarovskiy A.N., Siryaporn E., Hixson D.C., Akerley W. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell. Mol. Life Sci. 2002, 59:1198-1211.
12. Panvichian R., Orth K., Day M.L., Day K.C., Pilat M.J., Pienta K.J. Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res. 1998, 58:4667-4672.
13. Merlin J.L., Bour-Dill C., Marchal S., Bastien L., Gramain M.P. Resistance to paclitaxel induces time-delayed multinucleation and DNA fragmentation into large fragments in MCF-7 human breast adenocarcinoma cells. Anticancer Drugs 2000, 11:295-302.
14. Galimberti F., Thompson S.L., Ravi S., Compton D.A., Dmitrovsky E. Anaphase catastrophe is a target for cancer therapy. Clin. Cancer Res. 2011, 17:1218-1222.
15. Bagheri-Yarmand R., Biernacka A., Hunt K.K., Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis leading to chromosome missegregation and centrosome amplification. Cancer Res. 2010, 70:5074-5084.
16. Wu Q., Sahasrabudhe R.M., Luo L.Z., Lewis D.W., Gollin S.M., Saunders W.S. Deficiency in myosin light-chain phosphorylation causes cytokinesis failure and multipolarity in cancer cells. Oncogene 2010, 29:4183-4193.
17. Caruso R., Fedele F., Lucianò R., Branca G., Parisi C., Paparo D., Parisi A. Mitotic catastrophe in malignant epithelial tumors: the pathologist's viewpoint. Ultrastruct. Pathol. 2011, 35:66-71.
18. Komata T., Kanzawa T., Takeuchi H., Germano I.M., Schreiber M., Kondo Y., Kondo S. Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells. Br. J. Cancer 2003, 88:1277-1280.
19. Kirla R.M., Haapasalo H.K., Kalimo H., Salminen E.K. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 2003, 97:644-648.
20. Korkolopoulou P., Christodoulou P., Konstantinidou A.E., Thomas-Tsagli E., Kapralos P., Davaris P. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum. Pathol. 2000, 31:751-760.
21. Li M., Zhang Z., Hill D.L., Wang H., Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 2007, 67:1988-1996.
22. Gao N., Zhang Z., Jiang B.H., Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun. 2003, 310:1124-1132.
23. Ananthanarayanan V., Deaton R.J., Amatya A., Macias V., Luther E., Kajdacsy-Balla A., Gann P.H. Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays. Hum. Pathol. 2011, 42:873-881.
24. Wolters T., Vissers K.J., Bangma C.H., Schröder F.H., van Leenders G.J. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. BJU Int. 2010, 106:280-286.
25. Trotman L.C., Alimonti A., Scaglioni P.P., Koutcher J.A., Cordon-Cardo C., Pandolfi P.P. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006, 441:523-527.
26. van Duijn P.W., Trapman J. PI3K/Akt signaling regulates p27(kip1) expression via Skp2 in PC3 and DU145 prostate cancer cells but is not a major factor in p27(kip1) regulation in LNCaP and PC346 cells. Prostate 2006, 66:749-760.
27. Subbiah V., Naing A., Brown R.E., Chen H., Doyle L., LoRusso P., Benjamin R., Anderson P., Kurzrock R. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One 2011, 6:e18424.
28. Bashir T., Pagano M. Cdk1: the dominant sibling of Cdk2. Nat. Cell Biol. 2005, 7:779-781.
29. Gérard C., Goldbeter A. Temporal self-organization of the cyclin/Cdk network driving the mammalian cell cycle. Proc. Natl. Acad. Sci. USA 2009, 106:21643-21648.
30. Ihle N.T., Lemos R., Wipf P., Yacoub A., Mitchell C., Siwak D., Mills G.B., Dent P., Kirkpatrick D.L., Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009, 69:143-150.
31. Kim E.H., Kim H.S., Kim S.U., Noh E.J., Lee J.S., Choi K.S. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 2005, 24:6877-6889.
32. Hassan K.A., Ang K.K., El-Naggar A.K., Story M.D., Lee J.I., Liu D., Hong W.K., Mao L. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res. 2002, 62:6414-6417.
33. Gwinn D.M., Asara J.M., Shaw R.J. Raptor is phosphorylated by cdc2 during mitosis. PLoS One 2010, 5:e9197.
34. Lee S.R., Park J.H., Park E.K., Chung C.H., Kang S.S., Bang O.S. Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. J. Cell Physiol. 2005, 205:270-277.
35. D. Hiraoka, E. Okumura, T. Kishimoto, Turn motif phosphorylation negatively regulates activation loop phosphorylation in Akt, Oncogene, 2011. [Epub ahead of print].
36. Li X., Wang G., Zhao J., Ding H., Cunningham C., Chen F., Flynn D.C., Reed E., Li Q.Q. Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol. Life Sci. 2005, 62:894-904.
37. Kim E.H., Kim S.U., Choi K.S. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 2005, 24:838-849.
38. Huang J.M., Sheard M.A., Ji L., Sposto R., Keshelava N. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. Mol. Cancer Ther. 2010, 9:3289-3301.